MDX 1203

Drug Profile

MDX 1203

Alternative Names: MDX-1203

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Alkylating agents; CD70 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma; Renal cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in USA (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Renal-cancer in USA (IV, Infusion)
  • 30 Nov 2012 Bristol-Myers Squibb completes a phase I trial in Non-Hodgkin's lymphoma and Renal cancer in USA (NCT00944905)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top